ADC Therapeutics SA ADCT

ADCT Company Overview

ADC Therapeutics SA is a clinical-stage biotechnology company focused on the development and commercialization of antibody-drug conjugates (ADCs) for the treatment of hematologic malignancies and solid tumors. The company operates within the oncology biopharmaceutical industry and develops targeted therapies designed to deliver cytotoxic payloads directly to cancer cells while limiting systemic exposure. Its lead commercial product is ZYNLONTA (loncastuximab tesirine-lpyl), an ADC approved in the United States for certain patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company’s broader pipeline includes ADC candidates targeting both blood cancers and solid tumors through proprietary linker and payload technologies.

ADC Therapeutics was founded in 2011 and is headquartered in Lausanne, Switzerland. The company evolved from an early-stage oncology research organization into a publicly traded biotechnology company listed on the New York Stock Exchange under the ticker ADCT. Its strategic positioning is based on specialized expertise in pyrrolobenzodiazepine (PBD)-based ADC technology, targeted oncology drug development, and partnerships with larger pharmaceutical and biotechnology firms. Revenue generation has historically been driven primarily by product sales of ZYNLONTA, licensing arrangements, and collaboration-related payments tied to development partnerships and research agreements.